Valuation: Virbac

Market Cap 2.78B 3.18B 2.55B 2.38B 4.51B 303B 4.58B 30.71B 11.9B 148B 11.93B 11.67B 511B P/E 2026 *
16.5x
P/E 2027 * 14.7x
Enterprise Value 2.9B 3.32B 2.66B 2.48B 4.71B 316B 4.78B 32.04B 12.42B 155B 12.45B 12.18B 534B EV / Sales 2026 *
1.87x
EV / Sales 2027 * 1.71x
Free-Float
49.03%
Yield 2026 *
0.53%
Yield 2027 * 0.62%
1 day+6.04%
3 months+6.04%
6 months-6.49%
Current year-6.49%
Current year 384.75
Extreme 384.75
408
1 year 384.75
Extreme 384.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 2025-08-31
Chief Executive Officer 50 2024-09-26
Chief Operating Officer 64 2021-12-31
Director TitleAgeSince
Chairman 61 2006-03-31
Director/Board Member 68 2010-07-27
Director/Board Member 65 2017-09-04
Change 5-day change 1-year change 3-year change Capi.($)
+6.04%-.--% - - 3.15B
+3.24%-3.88%-52.98%-56.56% 30.37B
+3.78%+2.59%+69.84%+148.51% 12.03B
-1.18%-7.74%-14.64%+4.64% 3.83B
+1.36%-0.99%+50.06%+25.76% 1.9B
+3.08%0.00%-26.50%+17.77% 1.59B
+3.61%+4.49%+19.04%+142.77% 1.3B
+1.80%+3.31%-21.89%-13.99% 1.01B
+1.13%-0.14%-2.31%-21.44% 940M
+0.99%+1.50%-16.87%-47.69% 909M
Average +2.38%+0.61%+0.42%+22.20% 5.99B
Weighted average by Cap. +3.06%-3.58%-14.60%+5.05%

Financials

2026 *2027 *
Net sales 1.55B 1.77B 1.42B 1.32B 2.51B 168B 2.55B 17.1B 6.63B 82.63B 6.64B 6.5B 285B 1.64B 1.88B 1.51B 1.4B 2.66B 179B 2.71B 18.13B 7.03B 87.61B 7.05B 6.89B 302B
Net income 167M 191M 153M 143M 271M 18.2B 276M 1.85B 716M 8.93B 718M 702M 30.75B 190M 218M 175M 163M 309M 20.72B 314M 2.1B 815M 10.16B 817M 800M 35.02B
Net Debt 121M 138M 111M 104M 196M 13.18B 200M 1.34B 518M 6.47B 520M 509M 22.28B 26.49M 30.32M 24.33M 22.69M 43.01M 2.89B 43.73M 293M 114M 1.42B 114M 111M 4.88B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
331.50EUR
Average target price
412.88EUR
Spread / Average Target
+24.55%

Quarterly revenue - Rate of surprise